Inactive Instrument

Pfenex Inc.

Equities

PFNX

US7170711045

Biotechnology & Medical Research

Pfenex Inc. Appoints Dr. Shawn A. Scranton as Chief Operating Officer, Effective October 1, 2018

September 11, 2018 at 08:00 am

Pfenex Inc. announced that Dr. Shawn A. Scranton, will be joining Pfenex as its Chief Operating Officer, effective October 1, 2018. Dr. Scranton previously served as Chief Scientific Officer at Sentynl Therapeutics Inc.

Latest news about Pfenex Inc.

Pfenex Inc.(AMEX:PFNX) dropped from S&P TMI Index	20-09-30	CI
Pfenex Inc.(AMEX:PFNX) dropped from S&P Global BMI Index	20-09-30	CI
Pfenex Inc.(AMEX:PFNX) dropped from Russell 3000 Growth Index	20-09-29	CI
Pfenex Inc.(AMEX:PFNX) dropped from Russell Small Cap Comp Growth Index	20-09-29	CI
Pfenex Inc.(AMEX:PFNX) dropped from Russell 3000 Index	20-09-29	CI
Pfenex Inc.(AMEX:PFNX) dropped from Russell 2000 Growth Index	20-09-29	CI
Pfenex Inc.(AMEX:PFNX) dropped from Russell 2000 Index	20-09-29	CI
Pfenex Inc.(AMEX:PFNX) dropped from Russell 2500 Growth Index	20-09-29	CI
Pfenex Inc.(AMEX:PFNX) dropped from Russell 2500 Index	20-09-29	CI
Pfenex Inc.(AMEX:PFNX) dropped from Russell Small Cap Completeness Index	20-09-29	CI
Pfenex Inc.(AMEX:PFNX) dropped from Russell 2500 Growth-Dynamic Index	20-09-29	CI
Pfenex Inc.(AMEX:PFNX) dropped from Russell 2500 Dynamic Index	20-09-29	CI
Pfenex Inc.(AMEX:PFNX) dropped from Russell 2000 Growth-Dynamic Index	20-09-29	CI
Pfenex Inc.(AMEX:PFNX) dropped from Russell Microcap Growth Index	20-09-29	CI
Pfenex Inc.(AMEX:PFNX) dropped from Russell Microcap Index	20-09-29	CI
Pfenex Inc.(AMEX:PFNX) dropped from Russell 2000 Dynamic Index	20-09-29	CI
Ligand Pharmaceuticals Incorporated completed the acquisition of Pfenex Inc..	20-09-28	CI
Ligand Pharmaceuticals Incorporated signed a definitive agreement to acquire Pfenex Inc. for approximately $460 million.	20-08-09	CI
Transcript : Pfenex Inc., Q2 2020 Earnings Call, Aug 06, 2020	20-08-06
Pfenex Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-06	CI
Pfenex Inc. Announces Positive European CHMP Opinion for Pf708 and New Partnership in Latin America, and Provides Crm197 Business Update	20-06-26	CI
Pfenex Inc. Announces U.S. Commercial Launch of Teriparatide Injection	20-06-12	CI
Transcript : Pfenex Inc. - Shareholder/Analyst Call	20-05-08
Transcript : Pfenex Inc., Q1 2020 Earnings Call, May 07, 2020	20-05-07
Pfenex Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-07	CI

Chart Pfenex Inc.

Duration

Period

More charts

Company Profile

Pfenex Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Its next advanced product candidates are PF530 and PF708. PF530 is a biosimilar candidate to Betaseron (interferon beta-1b). PF708 is being developed as a therapeutically equivalent peptide to Forteo (teriparatide), which is for the treatment of osteoporosis. In addition to its three advanced product candidates, its pipeline includes over four other biosimilar candidates, as well as vaccines and next generation biologic candidates. Its product candidates are enabled by its protein production platform, Pfenex Expression Technology. It is also developing Px563L, an anthrax vaccine candidate, and Px533 as a prophylactic vaccine candidate against malaria infection.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+16.24%	122B
REGENERON PHARMACEUTICALS, INC.	+17.37%	114B
ARGENX SE	+19.62%	25.71B
BIONTECH SE	-25.87%	19.02B
GENMAB A/S	-20.21%	15.83B
BEIGENE, LTD.	-19.83%	15.32B
WUXI APPTEC CO., LTD.	-47.37%	14.88B
SAREPTA THERAPEUTICS, INC.	+59.95%	14.82B
NEUROCRINE BIOSCIENCES, INC.	+4.74%	14.1B

Bio Therapeutic Drugs